tyrosine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2786 60-18-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tyrosine
  • L-Tyrosine
  • (S)-Tyrosine
A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.
  • Molecular weight: 181.19
  • Formula: C9H11NO3
  • CLOGP: -2.22
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 83.55
  • ALOGS: -1.37
  • ROTB: 3

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal growth restriction 63.26 26.19 15 680 7538 63480789
Infantile apnoea 44.55 26.19 8 687 1025 63487302
Selective eating disorder 38.99 26.19 8 687 2064 63486263
Cerebral haemorrhage 31.33 26.19 12 683 30717 63457610
Device related sepsis 28.44 26.19 7 688 4087 63484240

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:50733 Dietary Supplement
CHEBI has role CHEBI:64416 arogenate dehydrogenase inhibitors
CHEBI has role CHEBI:78675 fundamental metabolites
CHEBI has role CHEBI:83056 Daphnia magna metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.27 acidic
pKa2 10.4 acidic
pKa3 9.25 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Large neutral amino acids transporter small subunit 1 Transporter IC50 4.17 CHEMBL

External reference:

IDSource
4018678 VUID
N0000146989 NUI
D00022 KEGG_DRUG
4018678 VANDF
C0041485 UMLSCUI
CHEBI:18186 CHEBI
TYR PDB_CHEM_ID
CHEMBL925 ChEMBL_ID
DB00135 DRUGBANK_ID
D014443 MESH_DESCRIPTOR_UI
6057 PUBCHEM_CID
6174 INN_ID
4791 IUPHAR_LIGAND_ID
42HK56048U UNII
10962 RXNORM
15487 MMSL
187423 MMSL
40047 MMSL
NOCODE MMSL
d07831 MMSL
003449 NDDF
27378009 SNOMEDCT_US
418246001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3200 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3205 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 24 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 24 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 32 mg INTRAVENOUS NDA 20 sections